-
Self-Microemulsifying System Dramatically Boosts Luteolin Up
2026-06-05
The reference study introduces a luteolin-loaded self-microemulsifying drug delivery system (Luteolin-SME) that markedly enhances oral bioavailability by inhibiting P-glycoprotein efflux. This innovation achieved a 29-fold increase in systemic exposure and demonstrated low cytotoxicity, offering a robust approach for improving the pharmacokinetics of poorly absorbed natural compounds.
-
Dual Enzyme-Responsive Zwitterionic Peptide Achieves Cancer
2026-06-05
This study introduces a zwitterionic peptide amphiphile engineered for dual enzyme responsiveness, enabling highly selective lysosomal self-assembly in cancer cells. The approach delivers an exceptional cancer selectivity index and in vivo efficacy, offering new strategies for minimizing off-target toxicity in peptide-based therapeutics.
-
Self-Microemulsifying System Elevates Luteolin Bioavailabili
2026-06-04
This study presents a self-microemulsifying drug delivery system (SME) for luteolin, leveraging P-glycoprotein efflux inhibition to achieve a dramatic increase in oral bioavailability. The findings suggest a robust platform for enhancing the pharmacokinetic performance of bioactive flavonoids, with promising implications for pharmaceutical and nutraceutical development.
-
Advances in Silybin Chemistry: Implications for Milk Thistle
2026-06-04
Křen et al.'s review provides a comprehensive analysis of silybin—the principal flavonolignan in milk thistle extract—detailing its chemical structure, stereochemistry, and the evolution of preparative and derivatization methods. These insights underpin silybin’s role as a versatile reference compound for oxidative stress, hepatocellular carcinoma, and metabolic research, while clarifying limitations in formulation and experimental transferability.
-
High-Content Drug Screening Reveals Src Vulnerabilities in C
2026-06-03
This study applied image-based high-content drug screening to uncover new therapeutic vulnerabilities in conjunctival melanoma cell lines. Notably, Src kinase inhibition—exemplified by compounds such as Tirbanibulin dihydrochloride—emerged as a promising strategy, with implications for precision-targeted therapy development.
-
Merimepodib (VX-497): Transforming Antiviral and Immunology
2026-06-03
Merimepodib (VX-497) empowers researchers to precisely dissect nucleotide metabolism, offering robust, selective IMPDH inhibition for antiviral, cancer, and immunology studies. Its proven specificity and cross-species efficacy make it indispensable for high-impact experimental designs targeting guanine nucleotide biosynthesis.
-
Dopamine Inhibits Osteoclastogenesis via cAMP/PKA/CREB Pathw
2026-06-02
Wang et al. delineate how dopamine suppresses osteoclast differentiation by engaging the cAMP/PKA/CREB signaling axis in bone cells. Their work clarifies a neuroendocrine mechanism of bone remodeling, providing a molecular framework for future research into nervous system regulation of skeletal health.
-
FPH1 (BRD-6125): Advancing Hepatocyte Proliferation for Tran
2026-06-02
This article delivers mechanistic insights and strategic guidance for leveraging FPH1 (BRD-6125) in primary human hepatocyte culture and iPSC-derived hepatocyte workflows. By integrating recent advances in optogenetic gene regulation, we map out a forward-thinking strategy for translational researchers seeking scalable, donor-independent hepatic models and therapeutic platforms. The discussion critically bridges functional proliferation, emerging gene switches, and the evolving landscape of cell-based therapies.
-
Grazoprevir Hydrate (MK-5172): Clinical Pharmacology and Pre
2026-06-01
Explore the advanced clinical pharmacology of Grazoprevir hydrate (MK-5172 hydrate), an oral HCV NS3/4A protease inhibitor with unique efficacy in challenging hepatitis C populations. Learn how its pharmacokinetic profile and real-world outcomes inform best-practice decisions for diverse patient cohorts.
-
(-)-Epigallocatechin gallate (EGCG): Neuroprotection and Ant
2026-06-01
Explore how (-)-Epigallocatechin gallate (EGCG), a major green tea catechin, drives neuroprotection and antioxidant intervention in neurodegenerative disease models. This in-depth article uncovers EGCG’s mechanisms, translational potential, and unique research applications beyond standard apoptosis and antiangiogenic assays.
-
KX2-391 Dihydrochloride: Dual Src & Tubulin Inhibitor Benchm
2026-05-31
KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) is a dual mechanism small molecule that potently inhibits Src kinase and tubulin polymerization, with validated anticancer, antiviral, and neurotoxin-inhibitory activities. The compound demonstrates nanomolar potency in cellular assays, clinical efficacy in actinic keratosis, and a distinctive capacity to block BoNT/A activity in neuronal models.
-
Silymarin: Advanced Mechanistic Insights for Translational R
2026-05-30
Uncover the latest in silymarin applications, from its unique flavonolignan chemistry to cutting-edge mechanistic studies in oxidative stress and metabolic regulation. Explore how this milk thistle extract is shaping next-generation research models.
-
DAT Neuroimaging Tracks hESC-mDA Maturation in Parkinson’s M
2026-05-29
Goggi et al. (2020) demonstrate that dopamine transporter (DAT) neuroimaging enables accurate, non-invasive assessment of human embryonic stem cell-derived midbrain dopaminergic neuron (hESC-mDA) maturation following transplantation in a preclinical Parkinson’s disease model. This quantitative approach advances the evaluation of cell therapy efficacy and offers a valuable tool for translational research in neurodegenerative diseases.
-
Salinomycin in HCC Research: Beyond Proliferation Inhibition
2026-05-29
Discover the role of Salinomycin, a polyether ionophore antibiotic, in hepatocellular carcinoma research. This article explores novel assay insights and practical protocol guidance to advance your cancer cell apoptosis studies.
-
Tankyrase Inhibition Suppresses HCC Growth via Hippo Pathway
2026-05-28
Jia et al. (2017) reveal that selective tankyrase 1/2 inhibition reduces proliferation of hepatocellular carcinoma (HCC) cells by destabilizing YAP through AMOTL1/2 stabilization, implicating the Hippo cascade as a vulnerability in HCC. These findings expand the mechanistic understanding of tankyrase inhibitors beyond Wnt/β-catenin signaling, suggesting broader anticancer therapeutic potential.